Click on the citation below to open a *.pdf of the article.

 

Organotypic Model of Carcinogeneis and Chemoprevention

 

Benbrook, D.M.  Organotypic Cultures Represent Tumor Microenvironment for Drug Testing. (2006) Drug Discovery Today, Disease Models.  2:143-148.

 

Benbrook, D.M., Lightfoot, S., Ranger-Moore, J., Liu, T., Berry, W., Dozmorov, I. (2008) Karyometric and Gene Expression Analysis in an Organotypic Model of Endometrial Carcinogenesis and Chemoprevention. Gene Regulation and Systems Biology, 2: 1-22.

 

Kamelle, S., Sienko, A., Benbrook, D.M.  (2002) A Hormonally Responsive Model of Cycling Endometrium.  Fertility & Sterility, 78 (3):  596-602.

 

 

Drug Development

 

Flexible Heteroarotinoids:

 

Myers, T., Chengedza, S., Lightfoot, S., Pan, Y., Dedmond, D., Cole, L., Tang, Y., Benbrook, D.M.  (2008) Flexible Heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.  Investigational New Drugs, Published online: 18 September 2008.  http://www.springerlink.com/content/aj864j6707w47513/fulltext.pdf

 

Liu, T., Hannafon, B., Gill, L., Kelly, W., Benbrook, D.M. (2007) Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.  Molecular Cancer Therapeutics, 6: 1814-1822.

 

Liu, S., Brown, C.W., Berlin, K.D., Dhar, A., Guruswamy, S., Brown, D., Gardner, G.J., Birrer, M., J., & Benbrook, D.M. (2004) Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J. Med. Chem., 47: 999-1007.

 

Brown, C.S., Liu, S, Klucik, J., Brown, C.W., Berlin, K. D., Brennan, P.J., Devinder, K., Benbrook, D.M.  (2004) Novel heteroarotinoids as potential antagonists of Mycobacterium Bovis BCG.  J. Med. Chem, 47: 1008-1017.

 

Mic, F. A., Molotkov, A., Benbrook, D. M., and Duester, G. (2003) Retinoid activation of RAR but not RXR is sufficient for mouse embryonic development. Proceedings of the National  Academy of Sciences. 100: 7135-7140.

 

Chun, K.-H., Benbrook, D. M., Berlin, K. D., Honk, W. K., and Lotan, R. (2003) Induction of apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines by heteroarotinoids through a mitochondrial dependent pathway. Cancer Research, 63: 3826-3832.

 

 

First Generation Retinoid Heteroarotinoids:

 

Benbrook, D.M., Madler, M.M., Spruce, L.W., Birckbichler, P., Nelson, E.C., Subramanian, S., Weerasekare, G.M., Gale, J.B., Patterson, Jr., M.K., Wang, B., Wang, W., Lu, S., Rowland, T.C., DiSilvestro, P., Berlin, K.D., Lindamood, C., Hill, D.L.  (1997) Biologically active heteroarotinoids exhibit anticancer activity and decreased toxicity.  Journal of Medicinal Chemistry,  40: 3567-3583.

 

 

Dhar,A., Liu,S., Berlin, K.D., Madler, M.M., Ivey, R.T., Birckbichler, P.J., Lu, S., Zacheis, D., Brown, C.W., Klucik, J., Nelson, E.C., Benbrook, D.M. (1999) Synthesis and Structure-Activity Relationships of Nitrogen Heteroarotinoids.  Journal of  Medicinal Chemistry,  42: 3602-3614.

 

Zacheis, D., Dhar, A., Lu, S., Madler, M.M., Klucik, J. Brown, C.w., Liu, S., Clement, F., Subramanian, S., Weerasekare, G.M., Berlin, K.D., Gold, M., Houck, J.R., Fountain, K.R., Benbrook, D.M.  (1999)  Heteroarotinoids inhibit the growth of head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors.  Journal of  Medicinal Chemistry,  42: 4434-4445.

 

Heterocycle-Containing Retinoids:

 

Simoni, D., Roberti, M., Invidiata, F.P., Rondanin, R., Baruchello, R., Malagutti, C., Mazzali, A., Rossi, M., Grimaudo, S., Dusonchet, L., Meli, M., Raimondi, M.V., Landino, M., D’Alessandro, N., Tolomeo, M., Dhar, A., Lu, S.  Benbrook, D.M.  (2001)  Heterocycle-Containing Retinoids. Discovery of a Novel Isoxazole Arotinoid Possessing Potent Apoptotic Activity in Multidrug and Drug-Induced Apoptosis Resistant Cells.  Journal of Medicinal Chemistry, 44:2308-2318.

 

 

Translational Research

 

McMeekin, D.S., Sill, M.W., Darcy, K.M., Stearns-Kurosawa, D.J., Eaton, L., Yamada, J., Benbrook, D.M.  (2007)A phase II trial of thalidomide in patients with persistent or recurrent endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. Gynecologic Oncology, 105: 508-516.

 

Benbrook, D.M., Karlan B.Y. Promise and Problems of Translational Research. (2006) Gynecologic Oncology. 103: S14–S17

 

 

Older Publications

 

 

Benbrook, D.M. & Jones, N.C. (1990)  The Heterodimerization of Creb and Jun.  Oncogene, 5: 295-302.

 

Benbrook, D.M., Lu, S., Flanagan, C., Shen-Gunther, J., Angros, L.H., Lightfoot, S.A.  (1997) Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells.  Gynecological Oncology,  66: 114-121.